Bone Mineral Density and Lipid Metabolism After Alendronate and Strontium Ranelate Treatment

BACKGROUND/AIMS This study aimed to examine the alterations on metabolic changes in lipid levels and osteoporosis caused by alendronate (ALN) and strontium ranelate (SR) since shared biological linkages have great importance for new insights. Therefore, the treatments given for osteoporosis may also have a protective role against cardiovascular events. MATERIAL and METHODS In this retrospective study, 713 postmenopausal Turkish women were recruited. Biochemichal laboratory results and lipid parameters were recorded from the medical records of the patients. The lumbar spine (L1-L4), total femur (TF), and femoral neck (FN) were assessed for bone mineral density (BMD). Two hundred and sixty-three women were non-osteoporotic while 450 women were osteoporotic. Among the 450 osteoporotic women, 322 used ALN and 128 used SR. For each group, TF Dual energy X-ray absorptiometry (DEXA), FN DEXA and L1-L4 DEXA results and lipid changes were compared after 12-months treatment. RESULTS Patients who were given ALN showed significant improvement in the BMD measurement of L1-L4 and FN, but not in the results of TF DEXA. Significant changes similar to ALN were found in patients who were given SR. Patients using ALN had significantly higher levels of high-density lipoprotein (HDL). The SR group did not show marked lipid profile changes. CONCLUSION We demonstrated that osteoporosis in postmenopausal women may be related to atherosclerosis. ALN treatment has an enhancing effect on HDL levels; however, no effect was observed on serum lipid levels after SR treatment.


1. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet 2011; 377(9773): 1276-87. [Crossref]

2. Iacono MV. Osteoporosis: a national public health priority. J Perianesth Nurs 2007; 22(3): 175-82. [Crossref]

3. Tankó LB, Christiansen C, Cox DA, Geiger MJ, McNabb MA, Cummings SR. Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res 2005; 20(11): 1912-20. [Crossref]

4. Cui LH, Shin MH, Chung EK, Lee YH, Kweon SS, Park KS, et al. Association between bone mineral densities and serum lipid profiles of pre- and post-menopausal rural women in South Korea. Osteoporos Int 2005; 16(12): 1975-81. [Crossref]

5. Jeong TD, Lee W, Choi SE, Kim JS, Kim HK, Bae SJ, et al. Relationship between serum total cholesterol level and serum biochemical bone turnover markers in healthy pre- and postmenopausal women. Biomed Res Int 2014; 2014: 398397. [Crossref]

6. Hipmair G, Böhler N, Maschek W, Soriguer F, Rojo-Martínez G, Schimetta W, et al. Serum leptin is correlated to high turnover in osteoporosis. Neuro Endocrinol Lett 2010; 31(1): 155-60.

7. Hamerman D. Osetoporosis and atherosclerosis: biological linkages and the emergence of dual-purpose therapies. QJM 2005; 98(7): 467-84. [Crossref]

8. Buhaescu I, Izzedine H. Mevalonate pathway: a review of clinical and therapeutical implications. Clin Biochem 2007; 40(9-10): 575-84. [Crossref]

9. Cummins NM, Poku EK, Towler MR, O'Driscoll OM, Ralston SH. Clinical risk factors for osteoporosis in Ireland and the UK: a comparison of FRAX and QFracture Scores. Calcif Tissue Int 2011; 89(2): 172-7. [Crossref]

10. Mansueto P, Vitale G, Seidita A, Guarneri FP, Pepe I, Rinollo C, et al. Mevalonate pathway: role of bisphosphonate and statina. Acta Medica Mediterr 2011; 27(2): 85-95.

11. Reszka AA, Rodan GA. Nitrogen-containing bisphosphonate mechanism of action. Mini Rev Med Chem 2004; 4(7): 711-9. [Crossref]

12. Takaoka S, Yamaguchi T, Yano S, Yamauchi M, Sugimoto T. The calcium-sensing receptor is involved in strontium ranelate-induced osteoblast differentiation and mineralization. Horm Metab Res 2010; 42(9): 627-31. [Crossref]

13. Caudriltier A, Hurtel-Lemaire AS, Wattel A, Coumarie F, Godin C, Petit L, et al. Strontium ranelate decreases RANKL-induced osteoclastic differantion in vitro: involvement of the calcium sensing receptor. Mol Pharmacol 2010; 78(4): 569-76. [Crossref]

14. Hurtel-Lemaire AS, Mentaverri R, Caudrillier A, Cournaire F. The calcium sensing receptor is involved in strontium ranelate induced osteoclast apoptosis. New insights into the associated signaling pathways. J Biol Chem 2009; 284(1): 575-84. [Crossref]

15. Ammann P, Shen V, Robin B, Mauras Y, Bonjour JP, Rizzoli R. Strontium ranelate improves bone resistance by increasing bone mass and improving architecture in intact female rats. J Bone Miner Res 2004; 19(12): 2012-20. [Crossref]

16. Peng S, Liu XS, Wang T, Li Z, Zhou G, Luk KD, et al. In vivo anabolic effect of strontium on trabecular bone was associated with increased osteoblastogenesis of bone marrow stromal cells. J Orthop Res 2010; 28(9): 1208-14. [Crossref]

17. Fournier C, Perrier A, Thomas M, Laroche N, Dumas V, Rattner A, et al. Reduction by strontium of the bone marrow adiposity in mice and repression of the adipogenic commitment of multipotent C3H10T1/2 cells. Bone 2012; 50(2): 499-509. [Crossref]

18. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Praming-ham Study. Am J Med 1977; 62(5): 707-14. [Crossref]

19. Rye KA, Bursill CA, Iambert G, Tabet F, Barter PJ. The metabolism and antiatherogenic properties of HDL. J Lipid Res 2009; 50(Suppl): S195-200. [Crossref]

20. Jeon YK, Lee JG, Kim SS, Kim BH. Association between bone mineral density and metabolic syndrome in pre and postmenopausal women. Endocr J 2011; 58(2): 87-93. [Crossref]

21. Jeong IK, Cho SW, Kim SW, Choi HJ, Kim SY. Lipid profiles and bone mineral density in pre and postmenopausal women in Korea. Calcif Tissue Int 2010; 87(6): 507-12. [Crossref]

22. Makovey J, Chen JS, Hayward C, Williams FM, Sambrook PN. Association between serum cholesterol and bone mineral density. Bone 2009; 44(2): 208-213. [Crossref]

23. Go J-H, Song Y-M, Park J-H, Park J-Y, Choi Y-H. Association between Serum Cholesterol Level and Bone Mineral Density at Lumbar Spine and Femur Neck in Postmenopausal Korean Women. Korean J Fam Med 2012; 33(3): 166-73. [Crossref]

24. Jeong T-D, Lee W, Choi S-E, Kim JS, Kim H-K, Bae SJ, et al. Relationship between serum total cholesterol level and serum biochemical bone turnover markers in healthy pre- and postmenopausal women. BioMed Res Int 2014; 2014: 398397 [Crossref]

25. Das S, Crockett JC. Osteoporosis-a current view of pharmacological prevention and treatment. Drug Des Devel Ther 2013; 31(7): 435-48. [Crossref]

26. Rizzoli R, Laroche M, Krieg MA, Frieling I, Thomas T, Delmas P, et al. Strontium ranelate and alendronate have differing effects on distal tibia bone microstructure in women with osteoporosis. Rheumatol Int 2010;30(10): 1341-8. [Crossref]

27. Marie PJ. Strontium ranelate: a dual mode of action rebalancing bone turnover in favour of bone formation. Curr Opin Rheumatol 2006; 18(1): 11-5. [Crossref]

28. Rogers MJ, Gordon S, Benford HL. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000; 88(12Suppl): 2961-78. [Crossref]

29. Reginster JY, Hiligsmann M, Bruyere O. Strontium ranelate: long-term efficacy against vertebral, nonvertebral and hip fractures in patients with postmenopausal osteoporosis. Ther Adv Musculoskel Dis 2010; 2(3): 133-43. [Crossref]

30. You L, Sheng Z, Tang C, Chen L, Pan L, Chen J. High cholesterol diet increases osteoporosis risk via inhibiting bone formation in rats. Acta Pharmacologica Senica 2011; 32(12): 1408-504. [Crossref]

31. Yang Y, Liu G, Zhang Y, Xu G, Yi X, Liang Jet al. Association Between Bone Mineral Density, Bone Turnover Markers, and Serum Cholesterol Levels in Type 2 Diabetes. Front Endocrinol (Lausanne) 2018; 9: 646. [Crossref]

32. Dennison EM, Syddall HE, Aihie Sayer A, Martin HJ, Cooper C, Hertfordshire Cohort Study Group. Lipid profile, obesity and bone mineral density: The Hertfordshire Cohort Study. QJM 2007; 100(5): 297-303. [Crossref]

33. Adami S, Braga V, Guidi G, Gatti D, Gerardi D, Fracassi E. Chronic Intravenous aminobisphosphonate therapy increases high density lipoprotein cholesterol and decreases low density lipoprotein cholesterol. J Bone Miner Res 2000; 15(3): 599-604. [Crossref]

34. Celiloglu M, Aydin Y, Balci P, Kolamaz T. The effect of alendronate sodium on carotid artery intima-media thickness and lipid profile in women with postmenopausal osteoporosis. Menopause 2009; 16(4): 689-93. [Crossref]

Kaynak Göster

  • ISSN: 2149-7893
  • Yayın Aralığı: Yılda 4 Sayı
  • Başlangıç: 2016
  • Yayıncı: AVES Yayıncılık

1.3b 982

Sayıdaki Diğer Makaleler

Is Autonomic Function Impaired in Patients with Pseudoexfoliation Syndrome?


Configuration of Palliative Care Clinics and Integration with Home Health Care Services: Current Practice in Turkey

Mustafa Hamidullah TÜRKKANI, Tarkan ÖZDEMİR, Çiğdem ÖZDİLEKCAN, Fatih GÖKSEL

The Prevalence of Overweight and Obesity among Students between the Ages of 6 and 15 years in Konya

Şükran ARIKAN, Yetkin KAMUK, Serkan REVAN

White Spot Lesions: Recent Detection and Treatment Methods

İsmail Serhat SADIKOĞLU

Anesthesia Management in Patients with Covid-19

Ayşe Hande ARPACI, Berrin IŞIK

Close to Half of the Granulomatous Mastitis may be Tuberculosis Mastitis


Examination of the Relationship Between Exercise Barriers and Physical Activity, Sleep, and Fatigue in Older Individuals


Lasers for Removing Obturation Materials and Medicaments from the Root Canal: A Review


LGBT+ Individuals’ Sexual and Mental Health: A Comparison with Hetereosexual Group


Load Distribution in Tooth and Implant–Abutment Identical Cases

Muhammed Mutahhar ULUSOY, Hakan ARINÇ, Asiye Nehir ÖZDEN